Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
249
-49.9%
|
$65,238
$262.21 P/Share
|
|
Feb 16
2022
|
Peter M Neupert Director |
BUY
Open market or private purchase
|
Direct |
3,500
+11.21%
|
$920,500
$263.8 P/Share
|
|
Feb 15
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
207
-3.77%
|
$56,511
$273.98 P/Share
|
|
Feb 15
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
207
-3.04%
|
$56,511
$273.98 P/Share
|
|
Feb 14
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.38%
|
$20,944
$272.68 P/Share
|
|
Feb 14
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.12%
|
$20,944
$272.68 P/Share
|
|
Feb 14
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-2.32%
|
$217,328
$272.68 P/Share
|
|
Feb 14
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-1.08%
|
$29,376
$272.68 P/Share
|
|
Feb 14
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-0.62%
|
$75,344
$272.68 P/Share
|
|
Feb 14
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
778
-3.12%
|
$211,616
$272.68 P/Share
|
|
Feb 14
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-6.52%
|
$70,992
$272.68 P/Share
|
|
Feb 12
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
284
+4.85%
|
-
|
|
Feb 12
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
284
+3.96%
|
-
|
|
Feb 12
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
2,708
+7.08%
|
-
|
|
Feb 12
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
317
+3.08%
|
-
|
|
Feb 12
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
940
+2.07%
|
-
|
|
Feb 12
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,638
+9.25%
|
-
|
|
Feb 12
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
867
+18.46%
|
-
|
|
Feb 07
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
218
-3.96%
|
$60,386
$277.38 P/Share
|
|
Feb 07
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
204
-3.0%
|
$56,508
$277.38 P/Share
|
|
Feb 04
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
53
-4.29%
|
$14,681
$277.48 P/Share
|
|
Feb 04
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150
+10.82%
|
-
|
|
Feb 04
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-1.47%
|
$22,714
$277.48 P/Share
|
|
Feb 04
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+5.1%
|
-
|
|
Feb 04
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-14.26%
|
$22,991
$277.48 P/Share
|
|
Feb 04
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
267
+31.45%
|
-
|
|
Feb 04
2022
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-5.81%
|
$23,545
$277.48 P/Share
|
|
Feb 04
2022
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+16.07%
|
-
|
|
Feb 04
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
152
-2.18%
|
$42,104
$277.48 P/Share
|
|
Feb 04
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+7.45%
|
-
|
|
Feb 04
2022
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-7.89%
|
$391,124
$277.48 P/Share
|
|
Feb 04
2022
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,507
+16.39%
|
-
|
|
Feb 04
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-1.68%
|
$45,705
$277.48 P/Share
|
|
Feb 04
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+5.4%
|
-
|
|
Feb 04
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-0.65%
|
$79,222
$277.48 P/Share
|
|
Feb 04
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
970
+2.16%
|
-
|
|
Feb 04
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-1.64%
|
$45,705
$277.48 P/Share
|
|
Feb 04
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+5.27%
|
-
|
|
Feb 04
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
109
-0.74%
|
$30,193
$277.48 P/Share
|
|
Feb 04
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
373
+2.47%
|
-
|
|
Feb 03
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
172
-3.15%
|
$46,612
$271.81 P/Share
|
|
Feb 03
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
161
-2.45%
|
$43,631
$271.81 P/Share
|
|
Feb 02
2022
|
Jean Luc Belingard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.48%
|
$21,294
$273.18 P/Share
|
|
Feb 02
2022
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+4.51%
|
-
|
|
Feb 02
2022
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+28.55%
|
-
|
|
Feb 02
2022
|
Dwight Gary Gilliland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+9.89%
|
-
|
|
Feb 02
2022
|
Garheng Kong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+7.02%
|
-
|
|
Feb 02
2022
|
Richelle P Parham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+10.12%
|
-
|
|
Feb 02
2022
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+9.92%
|
-
|
|
Feb 02
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
103
-0.71%
|
$28,119
$273.18 P/Share
|